AlTi Global, Inc. Class A Common Stock

ALTI

AlTi Global, Inc. Class A (ALTI) is an investment firm focused on acquiring and managing private equity assets, including aerospace, defense, and related technology companies. The company emphasizes long-term value creation through strategic investments in innovative businesses within its targeted sectors.

$4.31 -0.05 (-1.15%)
🚫 AlTi Global, Inc. Class A Common Stock does not pay dividends

Company News

AlTi Global, Inc. (ALTI) Q1 Earnings and Revenues Miss Estimates
Zacks Investment Research • Zacks Equity Research • May 10, 2024

AlTi Global, Inc. (ALTI) delivered earnings and revenue surprises of -66.67% and 17.38%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Howard Hughes Holdings (HHH) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research • Zacks Equity Research • May 8, 2024

Howard Hughes Holdings (HHH) delivered earnings and revenue surprises of -51.43% and 19.89%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Moody's (MCO) Tops Q1 Earnings and Revenue Estimates
Zacks Investment Research • Zacks Equity Research • May 2, 2024

Moody's (MCO) delivered earnings and revenue surprises of 10.13% and 3.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Globe Life (GL) Soars 20.2%: Is Further Upside Left in the Stock?
Zacks Investment Research • Zacks Equity Research • April 15, 2024

Globe Life (GL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
Benzinga • Avi Kapoor • April 11, 2024

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session. Enliven Therapeutics announced proof of concept data from Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia. Enliven Therapeutics shares surged 26% to $24....

Related Companies